Skip to main content
Erschienen in: Diabetologia 10/2009

01.10.2009 | Short Communication

Circulating β-carotene levels and type 2 diabetes—cause or effect?

verfasst von: J. R. B. Perry, L. Ferrucci, S. Bandinelli, J. Guralnik, R. D. Semba, N. Rice, D. Melzer, R. Saxena, L. J. Scott, M. I. McCarthy, A. T. Hattersley, E. Zeggini, M. N. Weedon, T. M. Frayling, the DIAGRAM Consortium

Erschienen in: Diabetologia | Ausgabe 10/2009

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Circulating β-carotene levels are inversely associated with risk of type 2 diabetes, but the causal direction of this association is not certain. In this study we used a Mendelian randomisation approach to provide evidence for or against the causal role of the antioxidant vitamin β-carotene in type 2 diabetes.

Methods

We used a common polymorphism (rs6564851) near the BCMO1 gene, which is strongly associated with circulating β-carotene levels (p = 2 × 10−24), with each G allele associated with a 0.27 standard deviation increase in levels. We used data from the InCHIANTI and Uppsala Longitudinal Study of Adult Men (ULSAM) studies to estimate the association between β-carotene levels and type 2 diabetes. We next used a triangulation approach to estimate the expected effect of rs6564851 on type 2 diabetes risk and compared this with the observed effect using data from 4549 type 2 diabetes patients and 5579 controls from the Diabetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium.

Results

A 0.27 standard deviation increase in β-carotene levels was associated with an OR of 0.90 (95% CI 0.86–0.95) for type 2 diabetes in the InCHIANTI study. This association was similar to that of the ULSAM study (OR 0.90 [0.84–0.97]). In contrast, there was no association between rs6564851 and type 2 diabetes (OR 0.98 [0.93–1.04], p = 0.58); this effect size was also smaller than that expected, given the known associations between rs6564851 and β-carotene levels, and the associations between β-carotene levels and type 2 diabetes.

Conclusions/interpretation

Our findings in this Mendelian randomisation study are in keeping with randomised controlled trials suggesting that β-carotene is not causally protective against type 2 diabetes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ärnlöv J, Zethelius B, Riserus U et al (2009) Serum and dietary beta-carotene and alpha-tocopherol and incidence of type 2 diabetes mellitus in a community-based study of Swedish men: report from the Uppsala Longitudinal Study of Adult Men (ULSAM) study. Diabetologia 52:97–105PubMedCrossRef Ärnlöv J, Zethelius B, Riserus U et al (2009) Serum and dietary beta-carotene and alpha-tocopherol and incidence of type 2 diabetes mellitus in a community-based study of Swedish men: report from the Uppsala Longitudinal Study of Adult Men (ULSAM) study. Diabetologia 52:97–105PubMedCrossRef
2.
Zurück zum Zitat Kataja-Tuomola M, Sundell JR, Mannisto S et al (2008) Effect of alpha-tocopherol and beta-carotene supplementation on the incidence of type 2 diabetes. Diabetologia 51:47–53PubMedCrossRef Kataja-Tuomola M, Sundell JR, Mannisto S et al (2008) Effect of alpha-tocopherol and beta-carotene supplementation on the incidence of type 2 diabetes. Diabetologia 51:47–53PubMedCrossRef
3.
Zurück zum Zitat Reunanen A, Knekt P, Aaran RK, Aromaa A (1998) Serum antioxidants and risk of non-insulin dependent diabetes mellitus. Eur J Clin Nutr 52:89–93PubMedCrossRef Reunanen A, Knekt P, Aaran RK, Aromaa A (1998) Serum antioxidants and risk of non-insulin dependent diabetes mellitus. Eur J Clin Nutr 52:89–93PubMedCrossRef
4.
Zurück zum Zitat Liu S, Ajani U, Chae C et al (1999) Long-term beta-carotene supplementation and risk of type 2 diabetes mellitus: a randomized controlled trial. Jama 282:1073–1075PubMedCrossRef Liu S, Ajani U, Chae C et al (1999) Long-term beta-carotene supplementation and risk of type 2 diabetes mellitus: a randomized controlled trial. Jama 282:1073–1075PubMedCrossRef
5.
Zurück zum Zitat The ATBC Cancer Prevention Study Group (1994) The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. Ann Epidemiol 4:1–10CrossRef The ATBC Cancer Prevention Study Group (1994) The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. Ann Epidemiol 4:1–10CrossRef
6.
Zurück zum Zitat Song Y, Cook NR, Albert CM, Van Denburgh M, Manson JE (2009) Effects of vitamins C and E and β-carotene on the risk of type 2 diabetes in women at high risk of cardiovascular disease: a randomized controlled trial. Am J Clin Nutr 90:1–9CrossRef Song Y, Cook NR, Albert CM, Van Denburgh M, Manson JE (2009) Effects of vitamins C and E and β-carotene on the risk of type 2 diabetes in women at high risk of cardiovascular disease: a randomized controlled trial. Am J Clin Nutr 90:1–9CrossRef
7.
Zurück zum Zitat Whincup PH, Gilg JA, Papacosta O et al (2002) Early evidence of ethnic differences in cardiovascular risk: cross sectional comparison of British South Asian and white children. BMJ 324:635PubMedCrossRef Whincup PH, Gilg JA, Papacosta O et al (2002) Early evidence of ethnic differences in cardiovascular risk: cross sectional comparison of British South Asian and white children. BMJ 324:635PubMedCrossRef
8.
Zurück zum Zitat Timpson NJ, Lawlor DA, Harbord RM et al (2005) C-reactive protein and its role in metabolic syndrome: Mendelian randomisation study. Lancet 366:1954–1959PubMedCrossRef Timpson NJ, Lawlor DA, Harbord RM et al (2005) C-reactive protein and its role in metabolic syndrome: Mendelian randomisation study. Lancet 366:1954–1959PubMedCrossRef
9.
Zurück zum Zitat Rafiq S, Melzer D, Weedon MN et al (2008) Gene variants influencing measures of inflammation or predisposing to autoimmune and inflammatory diseases are not associated with the risk of type 2 diabetes. Diabetologia 51:2205–2213PubMedCrossRef Rafiq S, Melzer D, Weedon MN et al (2008) Gene variants influencing measures of inflammation or predisposing to autoimmune and inflammatory diseases are not associated with the risk of type 2 diabetes. Diabetologia 51:2205–2213PubMedCrossRef
10.
Zurück zum Zitat Ferrucci L, Perry JRB, Matteini A et al (2009) Common variation in the beta-carotene 15, 15′-monooxygenase 1 gene affects circulating levels of carotenoids: a genome-wide association study. Am J Hum Genet 84:123–133PubMedCrossRef Ferrucci L, Perry JRB, Matteini A et al (2009) Common variation in the beta-carotene 15, 15′-monooxygenase 1 gene affects circulating levels of carotenoids: a genome-wide association study. Am J Hum Genet 84:123–133PubMedCrossRef
11.
Zurück zum Zitat Ferrucci L, Bandinelli S, Benvenuti E et al (2000) Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study. J Am Geriatr Soc 48:1618–1625PubMed Ferrucci L, Bandinelli S, Benvenuti E et al (2000) Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study. J Am Geriatr Soc 48:1618–1625PubMed
12.
Zurück zum Zitat Zeggini E, Scott LJ, Saxena R et al (2008) Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 40:638–645PubMedCrossRef Zeggini E, Scott LJ, Saxena R et al (2008) Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 40:638–645PubMedCrossRef
13.
Zurück zum Zitat Coyne T, Ibiebele TI, Baade PD et al (2005) Diabetes mellitus and serum carotenoids: findings of a population-based study in Queensland, Australia. Am J Clin Nutr 82:685–693PubMed Coyne T, Ibiebele TI, Baade PD et al (2005) Diabetes mellitus and serum carotenoids: findings of a population-based study in Queensland, Australia. Am J Clin Nutr 82:685–693PubMed
14.
Zurück zum Zitat Hozawa A, Jacobs DR, Steffes MW et al (2006) Associations of serum carotenoid concentrations with the development of diabetes and with insulin concentration: interaction with smoking: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Epidemiol 163:929–937PubMedCrossRef Hozawa A, Jacobs DR, Steffes MW et al (2006) Associations of serum carotenoid concentrations with the development of diabetes and with insulin concentration: interaction with smoking: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Epidemiol 163:929–937PubMedCrossRef
15.
Zurück zum Zitat Montonen J, Knekt P, Jarvinen R, Reunanen A (2004) Dietary antioxidant intake and risk of type 2 diabetes. Diabetes Care 27:362–366PubMedCrossRef Montonen J, Knekt P, Jarvinen R, Reunanen A (2004) Dietary antioxidant intake and risk of type 2 diabetes. Diabetes Care 27:362–366PubMedCrossRef
16.
Zurück zum Zitat Ylonen K, Alfthan G, Groop L et al (2003) Dietary intakes and plasma concentrations of carotenoids and tocopherols in relation to glucose metabolism in subjects at high risk of type 2 diabetes: the Botnia Dietary Study. Am J Clin Nutr 77:1434–1441PubMed Ylonen K, Alfthan G, Groop L et al (2003) Dietary intakes and plasma concentrations of carotenoids and tocopherols in relation to glucose metabolism in subjects at high risk of type 2 diabetes: the Botnia Dietary Study. Am J Clin Nutr 77:1434–1441PubMed
17.
Zurück zum Zitat Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G (2008) Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 27:1133–1163PubMedCrossRef Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G (2008) Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 27:1133–1163PubMedCrossRef
18.
Zurück zum Zitat Kathiresan S, Melander O, Anevski D et al (2008) Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 358:1240–1249PubMedCrossRef Kathiresan S, Melander O, Anevski D et al (2008) Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 358:1240–1249PubMedCrossRef
19.
Zurück zum Zitat Willer CJ, Sanna S, Jackson AU et al (2008) Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 40:161–169PubMedCrossRef Willer CJ, Sanna S, Jackson AU et al (2008) Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 40:161–169PubMedCrossRef
Metadaten
Titel
Circulating β-carotene levels and type 2 diabetes—cause or effect?
verfasst von
J. R. B. Perry
L. Ferrucci
S. Bandinelli
J. Guralnik
R. D. Semba
N. Rice
D. Melzer
R. Saxena
L. J. Scott
M. I. McCarthy
A. T. Hattersley
E. Zeggini
M. N. Weedon
T. M. Frayling
the DIAGRAM Consortium
Publikationsdatum
01.10.2009
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 10/2009
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1475-8

Weitere Artikel der Ausgabe 10/2009

Diabetologia 10/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.